Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Evofem Biosciences, Inc. (EVFM)
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues | 100.0% | 100.0% | 100.0% | | | | | |
| Cost of goods sold | 26.2% | 49.2% | 104.9% | | | | | |
| Gross profit | 73.8% | 50.8% | -4.9% | | | | | |
| Sales and marketing | 261.0% | 1372.5% | 12660.8% | | | | | |
| Research and development | 148.7% | 401.9% | 3822.9% | | | | | |
| General and administrative | 163.7% | 299.7% | 6745.5% | | | | | |
| EBITDA | -493.6% | -2010.9% | -23166.4% | | | | | |
| Depreciation | 6.0% | 12.4% | 67.7% | | | | | |
| EBIT | -499.6% | -2023.3% | -23234.1% | | | | | |
| Pre-tax income | -455.3% | -2488.8% | -31907.0% | | | | | |
| Income taxes | 0.3% | 0.2% | 0.9% | | | | | |
| Net income | -463.3% | -2501.7% | -31907.8% | | | | | |
|